Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. AGNPF AGN AGW, has completed a feasibility study and has finalized its clinical trial design for a 40 patient phase 2 ...

Algernon Pharmaceuticals’ AGNPF wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) ...

VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatry VLS-01 ...

As we venture further into this new era of psychedelic innovation and discovery, more folks are becoming aware of the potential benefits of substances like psilocybin, LSD, or ketamine. But what about ...

-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- About the CYB004-E Study The CYB004-E study is an adaptive, ...

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0 ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing ...

A Canadian-based pharmaceutical company has received approval to conduct a clinical study of the psychedelic compound DMT as a treatment for stroke. Under the plan, pharmaceutical development company ...

A $1.5 million gift to UC San Diego will help fund a research program into the biological and psychological effect of a powerful psychedelic in humans, it was announced Tuesday. N, ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, ...